IRCT20231108059993N9 IRCT 2025-11-18 Actero Middle East Pharmaceutical Company Comparative bioequivalence study of the Eltrombopag 50 mg Tablet Manufactured by Actero Middle East Pharmaceutical Company Comparative Bioequivalence Study of the Eltrombopag 50 mg Tablet Manufactured by Actero Middle East Pharmaceutical Company by Innovative Company 2025-11-16 anticipated 24 Complete https://irct.ir/trial/86791 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Crossover, Purpose: Other, Randomization description: In order to randomly assign individuals to two groups, 24 cards numbered 1 to 24 in sealed envelopes placed in random order will be used. Each volunteer will pick an envelope after entering the study, and those who picked numbers 1-12 will be placed in group A and those who picked numbers 13-24 will be placed in group B. Volunteers in group A will receive the Iranian drug and volunteers in group B will receive the brand drug, and blood will be drawn at specific intervals according to a specific protocol. After a 2-week cleansing period, cross-over, those who have taken the Iranian drug will take the Brand drug and those who have taken the foreign drug will take the Iranian drug, and blood will be drawn again at different intervals. The blood draw results of each person in the second series of blood draws will be compared with their own blood draw results in the first round, Blinding description: This study is a double-blind clinical trial. Eltrombopag 50 mg tablets are removed from their packaging by the investigator and placed in identical, coded containers. Except for the principal investigator, neither the patient, the physician, nor other medical personnel, nor even those performing the concentration analysis, know which patient took which drug in the first or second round. Bioequivalence Healthy volunteers were enrolled in the study. Intervention group: Intervention group: The first intervention group, which has been randomly and double-blindly selected, will take the Iranian Eltrombopag 50 mg tablets, and the second group will take a brand drug . After a 2-week washout period, the first group will take the brand-name drug and the second group will take the Iranian drug, and blood will be taken from them at 17 time points.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is I haven't decided yet - the release schedule is still unknown.